The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preliminary analysis of the phase II study of pemetrexed plus carboplatin as first-line chemotherapy for elderly patients with advanced nonsquamous, non-small cell lung cancer.
Naoki Omachi
No relevant relationships to disclose
Motohiro Tamiya
No relevant relationships to disclose
Akihiro Tamiya
Honoraria - Lilly Japan
Tomoya Kawaguchi
No relevant relationships to disclose
Hiroyasu Kaneda
No relevant relationships to disclose
Kazuhiko Nakagawa
No relevant relationships to disclose
Koichi Goto
No relevant relationships to disclose
Yuichiro Ohe
No relevant relationships to disclose
Hiroaki Okamoto
No relevant relationships to disclose
Tetsuya Abe
No relevant relationships to disclose
Akira Yokoyama
No relevant relationships to disclose
Haruko Daga
No relevant relationships to disclose
Koji Takeda
No relevant relationships to disclose
Tomonori Hirashima
No relevant relationships to disclose
Shinji Atagi
No relevant relationships to disclose